Wednesday, June 07, 2023
Sol-Gel Technologies and Searchlight Pharma have officially signed exclusive licence agreements for the distribution and commercialisation of TWYNEO and EPSOLAY in the Canadian market.
As part of the agreement, Sol-Gel will receive potential upfront payments and milestones totalling up to $11 million for two drugs. These payments may be associated with regulatory approvals and sales milestones. Additionally, Sol-Gel will be entitled to royalty percentages based on the net sales in Canada.
The initial term of the agreement spans fifteen years, with the possibility of renewal for subsequent five-year periods. This collaboration aims to make these advanced dermatological treatments widely available to Canadian consumers, addressing their specific skincare needs.
TWYNEO and EPSOLAY are two new dermatology products developed by Sol-Gel Technologies. With the signing of these agreements, both companies aim to bring innovative dermatological solutions to patients in Canada.
TWYNEO is a combination cream that contains tretinoin (a retinoid) and benzoyl peroxide. It is used for the treatment of acne vulgaris in adults and paediatric patients 9 years of age and older. EPSOLAY is a cream that contains benzoyl peroxide at a concentration of 5 percent. It is specifically indicated for the treatment of inflammatory lesions associated with rosacea in adults.
